Skip to main content

Research Repository

Advanced Search

Nottingham Prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: A validation study

Lashen, Ayat G; Toss, Michael; Miligy, Islam; Rewcastle, Emma; Kiraz, Umay; Janssen, Emiel A M; Green, Andrew R; Quinn, Cecily; Ellis, Ian; Rakha, Emad

Nottingham Prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: A validation study Thumbnail


Authors

Ayat G Lashen

Michael Toss

Islam Miligy

Emma Rewcastle

Umay Kiraz

Emiel A M Janssen

Cecily Quinn

Ian Ellis

EMAD RAKHA Emad.Rakha@nottingham.ac.uk
Professor of Breast Cancer Pathology



Abstract

Aims
In this study, we validate the use of Nottingham Prognostic x (NPx), consisting of tumour size, tumour grade, progesterone receptor (PR) and Ki67 in luminal BC.

Materials and methods
Two large cohorts of luminal early-stage BC (n = 2864) were included. PR and Ki67 expression were assessed using full-face resection samples using immunohistochemistry. NPx was calculated and correlated with clinical variables and outcome, together with Oncotype DX recurrence score (RS), that is frequently used as a risk stratifier in luminal BC.

Results
In the whole cohort, 38% of patients were classified as high risk using NPx which showed significant association with parameters characteristics of aggressive tumour behaviour and shorter survival (P < 0.0001). NPx classified the moderate Nottingham Prognostic Index (NPI) risk group (n = 1812) into two distinct prognostic subgroups. Of the 82% low-risk group, only 3.8% developed events. Contrasting this, 14% of the high-risk patients developed events during follow-up. A strong association was observed between NPx and Oncotype Dx RS (P < 0.0001), where 66% of patients with intermediate risk RS who had subsequent distant metastases also had a high-risk NPx.

Conclusion
NPx is a reliable prognostic index in patients with luminal early-stage BC, and in selected patients may be used to guide adjuvant chemotherapy recommendations.

Citation

Lashen, A. G., Toss, M., Miligy, I., Rewcastle, E., Kiraz, U., Janssen, E. A. M., Green, A. R., Quinn, C., Ellis, I., & Rakha, E. (2024). Nottingham Prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: A validation study. Histopathology, 85(3), 468-477. https://doi.org/10.1111/his.15234

Journal Article Type Article
Acceptance Date May 28, 2024
Online Publication Date Jun 13, 2024
Publication Date 2024-09
Deposit Date Aug 16, 2024
Publicly Available Date Aug 19, 2024
Print ISSN 0309-0167
Electronic ISSN 1365-2559
Publisher Wiley
Peer Reviewed Peer Reviewed
Volume 85
Issue 3
Pages 468-477
DOI https://doi.org/10.1111/his.15234
Public URL https://nottingham-repository.worktribe.com/output/38382506
Publisher URL https://onlinelibrary.wiley.com/doi/10.1111/his.15234

Files






You might also like



Downloadable Citations